IL9 and cancer: In macrophage-enriched cancers, IL9 polarizes TAMs to the M1 phenotype and triggers antitumor immunity by inducing chemotactic recruitment and the in situ accumulation of antitumor immune cells, including dendritic cells (DC), macrophages, T cells, and NK cells in CXCL9- and CCL3-dependent manners.